CTRI/2021/11/038048尚未招募不适用
A Randomized, Multicenter, Multiple-dose, Two-treatment, Single-period, Parallel, Steady-State Bioequivalence Study of Mylan’s Paliperidone Prolonged-release Suspension for Injection, 350 mg and Janssen-Cilag’sTrevicta® Prolonged-release Suspension for Injection, 350 mg in Subjectswith Schizophrenia.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 300
- 试验地点
- 17
- 主要终点
- To evaluate the bioequivalence of Mylan’s Paliperidone Prolonged-release Suspension for Injection 350 mg of Mylan Laboratories Limited, India with Janssen-Cilag’s Trevicta 350 mg (equivalent to 546 mg Paliperidone Palmitate) in subjects with schizophrenia.
研究概览
简要总结
A bioequivalence study withPaliperidone Prolonged-releaseSuspension for Injection 350 mg insubjects with schizophrenia with the following objectives:
To demonstrate thebioequivalence of Mylan’s Paliperidone Prolonged-release Suspension forInjection 350 mg of Mylan Laboratories Limited, India with Janssen-Cilag’sTrevicta 350 mg (equivalent to 546 mg Paliperidone Palmitate) in subjects withschizophrenia
To evaluate the safety and tolerability of Mylan’sPaliperidone Prolonged-release Suspension for Injection, 350 mg in subjectswith schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified: 1.Male or on-pregnant, non-lactating female subjects between 18 and 65 years of age (both inclusive) 2.Patients having a clinical diagnosis of schizophrenia as per DSM V criteria.
- •3.Patients with established tolerability and responsiveness to oral paliperidone/risperidone or injectable paliperidone prior to screening 4.Subjects who are on a stable regimen of 350 mg three-month paliperidone palmitate prolonged-release suspension for injection (e.g. Trevicta® 350 mg) 5.Subjects who are clinically stable with no hospitalizations for exacerbation of psychiatric symptoms 6.Weight:Each subject is required to weigh at least 50 kg (110 lbs) for men and 48 kg (106 lbs) for women and have a Body Mass Index (BMI) value less than or equal to 35.0 kg/m2 but greater than or equal to 18.0 kg/m2.
排除标准
- •Subject candidates must not be enrolled in the study if they meet any of the following criteria: 1.Institutionalized subjects. 2.Subjects with history of alcohol or drug-dependence as per DSM-V criteria 3.Subjects with ingestion of any alcoholic beverage within the 24 hours 4.Subjects with ingestion of risperidone long acting injection 5.Subjects with depot injection or implant of any drug other than hormonal contraceptive or hormone replacement therapy 6.Subjects currently being treated with Clozapine, monoamine oxidase inhibitor (MAOI) antidepressants, electroconvulsive therapy 7.Use of any medication, herbal supplement, or vitamin known to induce or inhibit hepatic enzyme activity 8.Subjects with dementia related psychosis 9.Subjects with Clinical Global Impression.
- •Severity of illness (CGI-S) score of 5 or more 10.Subjects with suicidal ideation 11.Subjects with a history of Neuroleptic Malignant Syndrome (NMS) 12.History of any significant cardiovascular, hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychological, genitourinary, musculoskeletal disease, uncontrolled metabolic diseases, clinically significant laboratory results or malignancies by the Principal Investigator or Medical Sub-Investigator. 13.Use of drugs that prolong the QTc interval, 14.Subjects with positive HIV, hepatitis B antigen, hepatitis C antibody, RPR or VDRL test 15.Subjects with positive urine drug screen 16.Subjects with history or presence of tardive dyskinesia, seizures idiopathic Parkinson’s disease, cognitive and motor impairment. 17.Subjects with donation or loss of blood or plasma 18.Subjects with participation in any interventional clinical study 19.Subjects with allergy or hypersensitivity to paliperidone, risperidone, other related products, or any inactive ingredients 20.Subjects has clinical signs and symptoms consistent with COVID-19 or had severe COVID-19.
结局指标
主要结局
To evaluate the bioequivalence of Mylan’s Paliperidone Prolonged-release Suspension for Injection 350 mg of Mylan Laboratories Limited, India with Janssen-Cilag’s Trevicta 350 mg (equivalent to 546 mg Paliperidone Palmitate) in subjects with schizophrenia.
时间窗: after 5th dose
次要结局
- To evaluate the safety and tolerability of Mylan’s Paliperidone Prolonged-release Suspension for Injection, 350 mg in subjects with schizophrenia.(Safety will be assessed throughout the study , i.e., from signing of ICF to end)
研究者
研究点 (17)
Loading locations...
相似试验
已完成
1 期
A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This TreatmentSchizophreniaNCT03425552Pharmathen S.A.70
已完成
1 期
A Study of the Bioequivalence of 12 mg Paliperidone Extended Release Tablets Manufactured at Gurabo and VacavilleSchizophreniaNCT00790777Johnson & Johnson Pharmaceutical Research & Development, L.L.C.72
已完成
1 期
A Study of Paliperidone Blood Concentrations in Patients With Schizophrenia After Administration of Paliperidone PalmitateSchizophreniaNCT01110317Johnson & Johnson Pharmaceutical Research & Development, L.L.C.49
已完成
3 期
A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With SchizophreniaSchizophreniaNCT01529515Janssen Research & Development, LLC509
已完成
3 期
A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With SchizophreniaSchizophreniaNCT00604279Xian-Janssen Pharmaceutical Ltd.452